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Abstract 
GNAS, a gene encoding G-protein stimulating alpha subunit, is frequently mutated in 
intraductal papillary mucinous neoplasms (IPMNs), which is an indolent and slow-growing 
pancreatic neoplasm that secretes abundant mucin. GNAS mutation is not observed in 
conventional ductal adenocarcinomas of the pancreas. To determine the functional 
significance of GNAS mutation, the phenotypes and gene expression profiles of cells with 
exogenous expression of either wild-type or mutant (R201H) GNAS were examined in vitro, 
using the pancreatic cancer cell lines PK-8, PCI-35, and MIA PaCa-2. The exogenous 
expression of GNAS increased intracellular cyclic-adenine monophosphate (cAMP), 
particularly in the mutated GNAS transfectants; however, the degree of this upregulation 
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appeared to be cell-type specific. The exogenous expression of GNAS induced no obvious 
cell-growth promotion; rather, it suppressed the proliferation and anchorage-dependent 
growth of cells in vitro. The exogenous expression of GNAS induced varying degrees of 
alterations in global gene expression profiles. PK-8 was the cell line that was most sensitive 
to the exogenous expression of GNAS, as it exhibited drastic alterations in the gene expression 
profile and upregulation of MUC2 and MUC5AC. PCI-35 and MIA PaCa-2 cells were less 
sensitive and exhibited a lower number of genes with altered expression, with downregulation 
of mucin genes. MAPK activity contributed to mucin gene expression under active GNAS. 
These results indicate that the mutation in GNAS found in IPMNs can widely change gene 
expression profiles, with alteration of mucin gene expression. PK-8 cells expressing mutated 
GNAS exogenously can be used as an ideal in vitro model of IPMN. 
 
Background 
Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is a cystic neoplasm 
consisting of dilated ducts lined by neoplastic cells with abundant secreted mucin.
1-4)
 IPMN is 
regarded as a noninvasive precursor of invasive ductal adenocarcinoma of the pancreas. The 
prognosis of IPMN with an associated invasive carcinoma is poor, as it exhibits a 27–60% 
 3 
5-year survival rate, depending on the extent and histological type of the invasive 
component.
5-7)
 Recently, various somatic mutations in GNAS have been found in IPMN, i.e., 
41–66% of IPMN cases harbor recurrent mutations at codon 201 of GNAS,
8, 9)
 mostly R201H 
or R201C. Furthermore, GNAS mutations were not found in conventional ductal 
adenocarcinomas (PDACs) or other cystic neoplasms of the pancreas. Hence, mutated GNAS 
is considered as a key molecule that distinguishes IPMN from other pancreatic neoplasms. 
However, the function of mutated GNAS in pancreatic ductal cells is still unknown. 
GNAS encodes the guanine nucleotide-binding protein (G-protein) stimulating alpha subunit 
(Gs!). Gs! comprises a heterotrimeric G-protein complex with beta and gamma subunits and 
functions as a mediator in the G-protein-coupled receptor (GPCR) signaling pathway. 
Binding between ligands and the receptor leads to the activation of Gs! by exchanging 
guanine diphosphate (GDP) to guanine triphosphate (GTP) and dissociating from beta and 
gamma subunits. The activated Gs! transmits a stimulating signal to an effector, adenylyl 
cyclase, which releases cAMP. In turn, cAMP binds to cAMP-dependent protein kinase 
(PKA), which results in the activation of PKA and of subsequent downstream signaling 
cascades.
10)
 Gs! has an intrinsic hydrolysis activity that turns GTP to GDP, which inactivates 
itself. The mutations of GNAS commonly found in some tumors are missense mutations 
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substituting codon 201, i.e., R201H or R201C. These mutations of GNAS disrupt the intrinsic 
hydrolytic activity of the molecule and result in constitutive activation of Gs! and its effector 
adenylyl cyclase, leading to the autonomous synthesis of cAMP.
11)
 Somatic mutations in 
GNAS have been identified in various tumors, including thyroid carcinomas, adrenocortical 
lesions, pituitary tumors, kidney tumors, Leydig cell tumors, intramuscular myxoma, and 
adenoma of the colorectum.
11-15)
 These organs have endocrine or exocrine function, thus 
mutated GNAS is supposed to be associated with secretory function.  
 
Purpose 
Despite the known aberrant molecular functions of mutated GNAS, its effect on phenotypes of 
epithelial cells is poorly understood. To elucidate the functional significance of the mutated 
GNAS found in IPMN, experiments were performed using pancreatic cancer cell lines of 
ductal cell origin in vitro. 
 
Material and methods 
Pancreatic cancer cell lines 
The human pancreatic cancer cell lines PK-8, PCI-35, and MIA PaCa-2 were obtained and 
cultured. The PK-8 and PCI-35 were maintained in RPMI 1640 (Sigma-Aldrich, St. Louis, 
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Mo, USA) supplemented with 10% fetal bovine serum (PAA Laboratories GmbH, Austria). 
The MIA PaCa-2 was maintained in Dulbecco’s modified Eagle medium (DMEM) 
(Sigma-Aldrich) supplemented with 10% fetal bovine serum (PAA Laboratories GmbH). 
 
 
Construction of the expression vector of GNAS cDNA 
A cDNA of wild-type GNAS was amplified by PCR using a pooled cDNA prepared from a 
human fetal brain cDNA library (Agilent Technologies Inc., Santa Clara, CA, USA)), a paired 
primers of C1, 5!–TTTAAGCTTCCGCCGCCGCCATGGGCTGC–3!, and C2, 
5!–TTTCTCGAGGAGCAGCTCGTACTG–3! (italicized letters indicate restriction enzyme 
sequences, which were used to facilitate cloning), and the KOD Plus DNA polymerase system 
(TOYOBO, Osaka, Japan). The amplified product was cloned into a pcDNA 3.1/V5-His 
expression vector (Life Technologies, Carlsbad, CA, USA) at the HindIII and XhoI sites, to 
generate the wild-type GNAS-V5-His vector. Site-directed mutagenesis to create GNAS 
(R201H)-V5-His was performed using M1, 
5!–CCTGCTTCGCTGCCATGTCCTGACTTCTGG–3!, and M2, 
5!–AGAAGTCAGGACATGGCAGCGAAGCAGGTC–3! (bold letters indicate substitutions) 
and Quickchange Site directed mutagenesis kit (Agilent Technologies Inc.) according to the 
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manufacturer’s recommendations. The nucleotide sequences of the clones were verified using 
BigDye terminator and Genetic Analyzer (Life Technologies) according to the manufacturer’s 
recommendations. 
 
 
Transfection efficiency 
Cells were seeded at 4 " 10
5
 cells/well in 6-well plates and incubated for 24 hours at 37°C 
with 5% CO2. The pcDNA 3.1/mutant GNAS-V5-His vector was transfected into the cells 
with Lipofectamine 2000 reagent (Life Technologies) according to the manufacturer’s 
recommendations. 24h after the transfection, the cells were fixed with 100% methanol for 
immunocytochemistry. Blocking was performed with 10% fetal bovine serum (PAA 
Laboratories GmbH) in Phosphate-Buffered Saline (PBS), then anti-V5 fluorescein 
isothiocyanate (FITC)-conjugated antibody (Life Technologies) was added at the dilution of 
1:200. After 1h for the antibody incubation, expression of the recombinant fusions protein 
containing V5 epitope tag was detected under fluorescence microscopy (ZEISS LSM5 
PASCAL, Carl Zeiss Co., Oberkochen, Germany). Transfection efficiency was defined as the 
ratio of number of cells with fluorescent probes to all cells in the same field of microscopy.    
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Immunoblotting 
Cells were seeded at 4 " 10
5
 cells/well in 6-well plates and incubated for 24 hours at 37°C 
with 5% CO2. The pcDNA 3.1/V5-His vector, the wild-type GNAS-V5-His vector, or the 
mutant GNAS-V5-His vector were transfected into the cells with Lipofectamine 2000 reagent 
(Life Technologies) according to the manufacturer’s recommendations. 48h after the 
transfection to examine the transient effects, cells were lysed in radioimmunoprecipitation 
assay (RIPA) buffer (Sigma-Aldrich), supplemented with inhibitors of proteinases and 
phosphatases (Complete Mini and PhosSTOP; Roche Diagnostics). Denatured total cell lysate 
was separated in a 10-20% gradient polyacrylamide gel and blotted onto a polyvinylidene 
difluoride membrane (ATTO, Tokyo, Japan) by using an XV Pantera MP System (DRC Co., 
Ltd. Tokyo, Japan) according to the manufacturer’s recommendations. The primary 
antibodies used were a monoclonal anti-V5 antibody (Life Technologies), a monoclonal 
anti-Gs! antibody (BD Biosciences, San Diego, CA, USA), a monoclonal anti-MAPK, 
activated antibody (diphosphorylated ERK-1&2, Sigma-Aldrich, St. Louis, MO, USA), a 
monoclonal anti-ERK2 antibody (BD Biosciences), a monoclonal anti-phospho-Akt antibody 
(Cell Signaling Technology Inc., Danvers, MA, USA), a monoclonal anti-Akt antibody (Cell 
Signaling), and a monoclonal anti-beta actin antibody (Sigma-Aldrich). Blocking conditions 
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and the concentrations of antibodies were determined according to the manufacturers’ 
recommendations. Signals were visualized by reaction with the ECL Detection Reagent (GE 
Healthcare UK Ltd.) and captured digitally using an LAS 4000 Mini camera (Fujifilm Co. 
Ltd., Tokyo, Japan). 
 
cAMP analysis 
Cells were seeded at 4 " 10
5
 cells/well in 6-well plates for transfection and incubated for 24 
hours at 37°C with 5% CO2. The pcDNA 3.1/V5-His vector, the wild-type GNAS-V5-His 
vector, or the mutant GNAS-V5-His vector were transfected into cells using the Lipofectamine 
2000 reagent (Life Technologies) according to the manufacturer’s recommendations. They 
were collected in 100 mmol/L of HCl for lysis 48 h after transfection to examine the transient 
effects. The supernatant was applied to the cAMP assay, which was performed using a 
sensitive protein-binding EIA kit (Cayman Chemical Company, Ann Arbor, IL, USA), 
according to the manufacturer’s recommendations. Each experiment included data from three 
independent transfection wells. 
 
Colony formation assay 
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Cells were seeded at 4 " 10
5
 cells/well in 6-well plates and incubated for 24 hours at 37°C 
with 5% CO2. The colony formation assay was performed as described previously.
16)
 The 
pcDNA 3.1/V5-His vector, the wild-type GNAS-V5-His vector, or the mutant GNAS-V5-His 
vector were transfected into cells using the Lipofectamine 2000 reagent (Life Technologies) 
according to the manufacturer’s recommendations. For selection of stably transfected cells, 
G418 (Life Technologies) was administered at 400 #g/mL 48 h after the transfection. Four 
weeks after the transfection, the cells were fixed with 10% formalin solution and stained with 
hematoxylin. The area of colonies was assessed using the COLONY program (Fujifilm Co. 
Ltd.). Each experiment was performed using three dishes. The experiment was at least 
independently duplicated. 
 
Cell proliferation assay 
Cells were seeded at 5 " 10
3
 cells/well in 96-well plates with 100 #L of appropriate culture 
medium and incubated at 37°C with 5% CO2 for 24 hours. The pcDNA 3.1/V5-His vector, the 
wild-type GNAS-V5-His vector, or the mutant GNAS-V5-His vector were transfected into the 
cells with Lipofectamine 2000 reagent (Life Technologies) according to the manufacturer’s 
recommendations. A colorimetric cell proliferation 
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assay—3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay—was 
performed daily for 5 consecutive days (days 0 to 4) using the Cell Proliferation Kit I (Roche), 
as described previously.
17)
 Every 24 hours, the medium was replaced with 100 µl of 0.05% 
MTT/PBS ($) and then incubated for 1 hour. After the incubation, the MTT solution was 
removed by aspiration, and the cells were suspended in 100% ethanol. The 
spectrophotometrical absorbance of the formazan product was measured at 590 nm using 
microplate reader. Cell proliferation was defined in this experiment as the ratio of absorbance 
at day 3 to that at day 0. Each experiment included data from eight independent transfection 
wells. The experiment was at least independently duplicated. 
 
Flow cytometry 
Cells were seeded at 4 " 10
5
 cells/well in 6-well plates and incubated for 24 hours at 37°C 
with 5% CO2. The pcDNA 3.1/V5-His vector, the wild-type GNAS-V5-His vector, or the 
mutant GNAS-V5-His vector were transfected into the cells with Lipofectamine 2000 reagent 
(Life Technologies) according to the manufacturer’s recommendations. To examine the 
transient effects, 48h after the transfection procedure, the cells were dissociated by 
trypsinization. They were washed with PBS (-) and then fixed overnight with 70% ethanol at 
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$20°C. The fixed cells were pelleted, resuspended in 100 µl of hypotonic citric buffer (192 
mmol/L Na2HPO4, 4 mmol/L citric acid), and incubated for 20 minutes at room temperature. 
Then the cells were pelleted and suspended in PI/RNase/PBS (100 µg/ml propidium iodide, 
10 µg/ml RNase A). FACS Calibur System (BD Immunocytometry Systems) was used for 
analysis of DNA content. Flow cytometry for the analysis of the cell cycle was performed as 
described previously.
17)
 The experiment was at least independently duplicated. 
 
Quantitative real-time PCR assay 
Cells were seeded at 4 " 10
5
 cells/well in 6-well plates and incubated for 24 hours at 37°C 
with 5% CO2. The pcDNA 3.1/V5-His vector, the wild-type GNAS-V5-His vector, or the 
mutant GNAS-V5-His vector were transfected into the cells with Lipofectamine 2000 reagent 
(Life Technologies) according to the manufacturer’s recommendations. To examine the 
transient effects, the cells were dissociated by trypsinization 24h after the transfection 
procedure. Total RNAs were isolated from cultured cells using the RNeasy Mini kit (Qiagen, 
Hilden, Germany). Complementary DNAs were generated using the reverse transcription 
method, as described previously.
18)
 The TaqMan Gene Expression Assay and a 7500 
Real-Time PCR system (Life Technologies) were used to analyze transcriptional expression. 
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TaqMan primer sequences are 5!–TTGTCATGTACTCGGCCAAGGCCC–3! for MUC2 and 
5!–CAGCCCCGAGTTCAAGGGCAGGGTC–3! for MUC5AC. Standards for quantification 
were prepared by cloning of the TaqMan PCR product using the StrataClone PCR Cloning kit 
(Agilent Technologies Inc.). The assay was performed in 96-well plate with 20-µl reactions 
and with 40 cycles of denaturation at 95°C for 15 seconds followed by annealing at 60°C for 
1 minute. The expression of MUC2 and MUC5AC was assessed relative to the endogenous 
expression of GAPDH. Each experiment included data from three independent wells. The 
experiment was at least independently duplicated. 
 
Serial analysis of gene expression (SAGE) 
SAGE analysis was performed using the next-generation sequencer SOLiD system (Life 
Technologies) according to the manufacturer’s instructions. SOLiD-SAGE libraries were 
prepared from the same RNA samples isolated for real-time PCR. Each library was generated 
by using a kit (Life Technologies) to enhance barcoding of the samples. Adaptors contain a 
4-bp overhang (CATG), which complements the NlaIII digested double-stranded cDNA, an 
EcoP15I restriction enzyme recognition site, and PCR priming sites. Oligos for barcode 
addition were added to the tags by PCR. Each library is amplified in a PCR reaction with a 
 13 
different barcoded SOLiD™ 3’ Primer from the SOLiD™ RNA Barcoding Kit and a 
SOLiD™ 5’ Primer. The barcoded libraries were combined and sequenced on an Applied 
Biosystems SOLiD System. Sequenced tags were counted and cumulated to generate digital 
expression values of gene expression using the SOLiD-SAGE v1.10 software (Life 
Technologies). The raw tag counts of individual genes were normalized by dividing by the 
total tag counts and converted to obtain a value expressed in reads per million (RPM) tags. 
The values were expressed in the binary logarithm value (log2 RPM). 
 
Pathway analysis 
Gene sets from the SAGE analysis data were mapped on the Pathway map obtained from the 
Kyoto Encyclopedia of Genes and Genomes (KEGG) (http://www.genome.jp/kegg/) 
database.
19)
 
 
Semiquantitative RT–PCR 
Semiquantitative PCR was performed according to methods described previously using the 
GeneAmp PCR system 9700 (Life Technologies).
20)
 Optimized cycling conditions were 
determined for each gene, and the expression of GAPDH was monitored as an internal control. 
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The primers used in the RT-PCR reactions are shown in Table 1. The intensities of bands 
were measured digitally using the Image Gauge software (Fujifilm Co. Ltd.). 
 
U0126 treatment 
The MEK inhibitor U0126 (MERCK, Whitehouse Station, NJ) was dissolved in dimethyl 
sulfoxide (DMSO) and administered at 10 µmol/L. The culture medium of the cells was 
replaced with medium containing U0126 6 h after the transfection procedure. DMSO was 
administered at the same concentration in control treatments. Cells were collected 48 h after 
transfection and assayed. The experiment was at least independently duplicated. 
 
Statistical analyses 
The statistical analysis of flow cytometry results was performed using Pearson’s chi-squared 
test, and Student’s t-test was used for comparisons in other experiments. All analyses were 
performed using JMP 9 (SAS Institute, Cary, NC, USA). Statistical significance was set at p < 
0.05. 
 
Results 
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I. Exogenous expression of GNAS in pancreatic cancer cells 
First, expression vectors harboring either wild-type or mutated (R201H) GNAS cDNA with a 
V5-tag sequence were constructed and transfected into the pancreatic cancer cell lines PK-8, 
PCI-35, and MIA PaCa-2. The cells used in this study harbor gain-of-function mutations in 
KRAS: G12R in PK-8, G12D in PCI-35, and G12C in MIA PaCa-2 cells, but no mutation at 
codon 201 of GNAS, as described previously.
8)
 Transfection efficiency was investigated using 
fluorescent antibody technique, and was similar among the three cell lines (12.3% in PK-8, 
13.7% in PCI-35 and 12.7% in MIA PaCa-2 cells, Fig. 1). I confirmed the exogenous 
expression of GNAS by detecting the V5-tag protein using immunoblotting (Fig. 2A). I also 
confirmed the exogenous expression of Gs! induced by GNAS cDNA transfection using a 
specific anti-Gs! antibody. After the transfection of GNAS, cAMP was measured and found to 
be significantly increased, especially in transfectants with mutated GNAS (Fig. 2B). This 
result indicated that the transfected mutated GNAS functioned as a constitutive driver of the 
activation of cAMP signaling in these cells. Interestingly, the increase in the levels of cAMP 
was different among the cell lines, despite similar levels of exogenous protein expression. 
Subsequently, the expression of the extracellular signal-regulated kinase (ERK), 
phosphorylated ERK, v-Akt murine thymoma viral oncogene homolog (AKT), and 
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phosphorylated AKT were analyzed to determine the effects of the exogenous expression of 
Gs! on these signaling molecules. No obvious differences could be seen in expressions of 
these molecules among the vector-transfected control, wild-type GNAS transfectants, and 
mutated GNAS transfectants (Fig. 2A). 
 
II. Proliferation and anchorage-dependent growth of cells with exogenous expression of 
GNAS 
To elucidate effects of the exogenous GNAS expression on the proliferation and 
anchorage-dependent growth of cells, a colorimetric proliferation assay to determine its 
transient effect and a colony formation assay to assess the anchorage-dependent growth with 
stable effect were performed. I found that the exogenous expression of GNAS, either 
wild-type or mutant, had no promotive, but some suppressive, effects on the proliferation and 
the anchorage-dependent growth of the cells (Fig. 3 and Fig. 4A). Regarding the transient 
effect, the proliferation of MIA PaCa-2 cells was slightly but significantly suppressed (Fig. 
4A). Regarding the stable effect, the anchorage-dependent growth of PK-8 cells was evidently 
suppressed (Fig. 3). 
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III. Exogenous expression of GNAS does not alter the cell cycle 
Cell cycle assay was performed to determine the effects of the exogenous expression of 
GNAS. The results revealed that the exogenous expression of GNAS did not alter the cell cycle 
significantly (Fig. 4B). 
 
IV. Upregulation of mucin genes by exogenous expression of GNAS 
As noted above, IPMN characteristically secretes abundant mucin, which is a distinctive 
feature from those of PDAC. Mutations in GNAS are found exclusively in IPMNs (not in 
PDACs); hence, GNAS mutation is supposed to play a role in the secretion of abundant mucin. 
To determine the effect of mutated GNAS on the expression of mucin genes, I examined the 
expression of MUC2 and MUC5AC, which encode characteristic mucins that are abundantly 
expressed in IPMNs, in cells expressing wild-type or mutated GNAS exogenously using the 
real-time PCR assay (Fig. 5A and B). The results of this experiment demonstrated that 
expressions of MUC2 and MUC5AC genes were significantly upregulated in PK-8 cells; 
however on the contrary, downregulated in PCI-35 and MIA PaCa-2 cells by the exogenous 
expression of mutant GNAS (Fig. 5A and B). These results indicate that mutated GNAS 
promotes the expression of mucin genes in a cell-type-specific manner. 
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V. Global expression profiling under the exogenous expression of mutated GNAS 
As demonstrated above, the exogenous expression of mutated GNAS promoted mucin gene 
expression in PK-8, but not in PCI-35 or MIA PaCa-2 cells. To characterize these 
cell-type-specific reactions to the exogenous expression of mutated GNAS, global gene 
expression profiling using the serial analysis of gene expression (SAGE) method and 
next-generation sequencing technology were performed. In this experiment, expression 
profiles between cells transfected with the vector (Vec) and cells transfected with mutated 
GNAS (GM) were compared. The 15841 genes that were assayed were gated by marked 
expression differences in expression ratios of GM/Vec " 4 or # 0.25. I found that the number 
of gated genes was quite different among the different cell types: 2258 in PK-8, 260 in 
PCI-35, and 66 in MIA PaCa-2 cells, which indicated that PK-8 cells were quite sensitive to 
the exogenous expression of mutated GNAS regarding the alteration of gene expression (Fig. 
6). This remarkable alteration was attributable to the level of cAMP after transfection of the 
mutated GNAS, which was highest in PK-8 cells (Fig. 2B). Furthermore, among the three cell 
lines, PK-8 showed the highest GNAS expression in Vec, which approximated the 
endogenous expression in the cell line without transfection (9.95 in PK-8, 7.73 in PCI-35 and 
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8.76 in MIA PaCa-2 cells). These results indicate that PK-8 cells activated GPCR pathway 
(i.e., were GPCR-dependent cells), whereas PCI-35 and MIA PaCa-2 cells did not (i.e., were 
GPCR-independent cells). The result of SAGE analysis in PK-8 cells was validated using 
semi-quantitative PCR (Fig. 7). The validated genes were selected according to the following 
criteria from the SAGE results: gene expression ratio of GM/Vec " 2 or # 0.5 in PK-8 cells; 
gene expression values " 1 in any of the transfectants of PK-8; genes showing inverse 
expression between PK-8 and other cell lines (PCI-35 and MIA PaCa-2 cells); and genes 
previously described as being highly upregulated or downregulated in IPMN.
21)
 Moreover, 
some genes known to be associated with the expression of mucin were also validated.
22-24)
 
 
VI. Expression profiles of mucin genes 
Regarding the SAGE data, I focused on the effects of the exogenous expression of mutated 
GNAS on mucin gene expression (Table 2). Among the cell lines studied, PK-8 cells exhibited 
the most consistent upregulation of mucin genes, including MUC2, MUC5B, MUC6, MUC15, 
and MUC20. Some of these mucin genes are expressed abundantly in IPMNs.
25, 26)
 MUC1 
showed the most abundant expression among the mucin genes that were identified, and was 
upregulated in PCI-35 and MIA PaCa-2 cells, but downregulated in PK-8 cells. Interestingly, 
 20 
MUC1 is commonly expressed in PDACs, but rarely in IPMNs, and is usually observed in 
IPMN of the pancreatobiliary type, which is frequently associated with PDA.
27, 28)
 In addition, 
the expression of MUC1 and MUC2 is mutually exclusive in IPMN.
29)
 The elevation of 
MUC2 in PK-8 cells was consistent with the results of the gene expression assays performed 
using real-time PCR (Fig. 5A and B). Data for MUC5AC expression were not available in the 
SAGE analysis because a unique tag sequence useful for this analysis was not available in the 
data-processing pipeline. These results indicate that the exogenous expression of mutated 
GNAS alters the global expression of mucin genes; however, the extensiveness and magnitude 
of the alterations appeared to be cell-type specific, which seems to reflect distinct patterns of 
mucin expression between IPMN-type cells (PK-8) and PDAC-type cells (PCI-35 and MIA 
PaCa-2). 
 
VII. Alterations of global gene expressions in signaling pathways 
To determine the significance of the alterations in gene expression patterns in signaling 
pathways, the gated genes (GM/Vec " 4 or # 0.25) from the SAGE data were mapped on 
“Pathways in Cancer” in “Pathway Mapping”, available from KEGG 
(http://www.genome.jp/kegg/).
19)
 Maps with genes gated in PK-8 cells were shown as a 
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representative example (Fig. 8A and B). I found that the gated genes were mainly mapped on 
the phosphoinositide 3!-kinase (PI3K)–AKT signaling pathway and the mitogen-activated 
protein kinase (MAPK) signaling pathway. Then, the detailed gene expression patterns in 
these pathways among the cell lines were compared (Fig. 9). The gene expression patterns 
pertaining to these signaling pathways were changed drastically in PK-8 cells, but were 
almost unchanged in PCI-35 and MIA PaCa-2 cells, by the exogenous expression of the 
mutated GNAS, which was consistent with alterations in global gene expression profiles. In 
addition to the observation that the expression of genes in the signaling pathways in PK-8 
cells were considerably changed, the changed properties were completely different between 
the pathways. In the PI3K–AKT signaling pathway, genes encoding downstream effector 
molecules that were expressed in the nucleus were largely downregulated, whereas those that 
encoded upstream molecules were upregulated. In contrast, in the MAPK signaling pathway, 
genes encoding downstream effector molecules that were expressed in the nucleus were 
mainly upregulated, whereas those that encoded upstream molecules were mostly 
downregulated. These apparent opposite alterations between upstream genes and downstream 
genes in the pathways may be a result of feedback control.  
Next, genes possibly responsible for the suppression of the anchorage-dependent 
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growth of PK-8 cells by the exogenous expression of mutant GNAS as demonstrated by the 
colony formation assay were searched. According to Gene Ontology 
(http://www.geneontology.org/) information, I found that downregulated genes were 
categorized as involved in cell proliferation and growth in the biological process classification. 
Among the 2258 genes selected using this gating criteria in PK-8 cells, 284 genes were 
associated with cell proliferation and growth, and approximately 2/3 of the genes (181 of 284) 
were downregulated by the exogenous expression of mutated GNAS. Representative genes 
included SOCS1, ID1, PBXIP1, FKBPL, S1006A, STAP2, MARVELD1, and LGAL3BP. These 
genes were downregulated remarkably in PK-8, but not in PCI-35 or MIA PaCa-2 cells (Table 
3). 
 
VIII. MAPK contributes to mucin expression under exogenous expression of GNAS 
As demonstrated in the real-time PCR experiments, the exogenous expression of mutated 
GNAS upregulated MUC2 and MUC5AC in PK-8 cells, but downregulated these genes in 
PCI-35 and MIA PaCa-2 cells. In addition, SAGE results revealed that mutated GNAS 
robustly altered the gene expressions on PI3K–AKT and MAPK signaling pathway, 
indicating the effects of GNAS on these pathways. To examine the contribution of MAPK 
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pathway activity to mucin gene expression, I analyzed the alteration of gene expression 
patterns when MAPK activity was suppressed by U0126, a potent mitogen-activated protein 
kinase kinase (MAP2K) inhibitor. PK-8 and PCI-35 cells were used as representatives of 
GPCR-dependent and GPCR-independent cells, respectively. U0126 treatment after the 
exogenous expression of GNAS induced the downregulation of phosphorylated ERK, but did 
not lead to alterations of cAMP levels in both cell types (Fig. 10A and B). In PCI-35 cells, the 
expression levels of MUC2 and MUC5AC were almost equal between cells transfected with 
the vector, wild-type GNAS, and mutated GNAS; moreover, the inhibition of ERK remarkably 
suppressed the expression of both mucin genes (Fig. 10C and D). In PK-8 cells, in contrast, 
mucin genes were upregulated according to the cAMP levels, which varied according to the 
nature of the transfection, and the inhibition of ERK induced the suppression of MUC2 
expression, but upregulated MUC5AC (Fig. 10C and D). These results indicate that MAPK 
activity contributes to mucin gene expression, which appeared to be promoted consistently in 
PCI-35 cells (GPCR-independent cells), but varied inconsistently in PK-8 cells 
(GPCR-dependent cells, Fig. 11A and B).  
 
Discussion 
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In this study, in vitro phenotypes and gene expression profiles of cells with exogenous 
expression of either wild-type or mutated GNAS were examined. Exogenous expression of 
GNAS induced the elevation of intracellular cAMP levels, particularly in the mutated GNAS 
transfectants; the degree of this elevation appeared to be cell-type specific. The exogenous 
expression of GNAS induced no obvious promotion, but some suppression, of in vitro 
proliferation and anchorage-dependent growth. The exogenous expression of GNAS induced 
varying degrees of gene expression alterations. PK-8 cells were the most sensitive to the 
exogenous expression of GNAS, as they exhibited drastic alterations in gene expression 
profiles and upregulation of MUC2 and MUC5AC. PCI-35 and MIA PaCa-2 cells were less 
sensitive and showed a lower number of genes with altered expression, with downregulation 
of the mucin genes. MAPK activity contributed to mucin gene expression under the 
exogenous expression of GNAS. These results indicate that the mutation in GNAS found in 
IPMN plays a pivotal role in the alteration of gene expression patterns, and also in the 
alteration of mucin gene expressions. PK-8 cells expressing mutated GNAS exogenously can 
be used as an ideal in vitro model of IPMN. 
To assess the effects of the exogenous expression of GNAS on the phenotypes of 
ductal cells of the pancreas, pancreatic cancer cells of ductal origin were used in this study. In 
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fact, HPDE cell line, the non-transformed immortalized pancreatic ductal cell line, was tried 
to be employed for this study because  HPDE cell line seemed to be more appropriate for 
investigating the phenotypes of exogenous GNAS expression due to its less complicated 
molecular abnormalities, i.e., no KRAS mutation, than cancer cell lines. However, transfection 
efficiency was quite low and growth was attenuated by the transfection procedure itself in 
HPDE, therefore, the cells were not ideal for experiments in this study. On the other hand, 
pancreatic cancer cell lines, that are certainly pancreatic ductal cell origin, were satisfactory 
for their transfection efficiency and growth for investigation. Molecular abnormalities 
existing in cancer cell lines might complicate data for evaluation of untainted GNAS effects. 
A representative abnormality commonly found in pancreatic cancer cells is the 
gain-of-function mutation of KRAS, which was indeed the case in the cells used here, PK-8, 
PCI-35, and MIA PaCa-2, however critically for this study, they harbor no activating 
mutation in GNAS. Moreover, IPMNs commonly harbor the KRAS mutation besides GNAS 
mutation; therefore, pancreatic cancer cells with KRAS mutations could be used as an in vitro 
cellular model of IPMN to determine the phenotypes of the exogenous expression of mutated 
GNAS.
8, 9)
 In addition, unavailability of a cell line harboring mutated GNAS obtained from 
IPMN was also another crucial reason for use of these pancreatic cancer cell lines in this 
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study.  
In this study, results were obtained by in vitro experiments with mainly transient 
transfection procedures that induced artificial overexpression of GNAS. This could be one of 
the limitations of the current results for understanding GNAS functions in primary IPMNs. 
Establishment of stably transfected cells with natural level of expression can settle this issue, 
however, PK-8 with stable transfection of GNAS could not be established in this series of 
experiments potentially due to the suppressive effect on cell growth of transient expression of 
GNAS in this experimental setting. Besides, establishment of transgenic mice expressing 
mutated GNAS in the pancreas may ultimately uncover molecular functions of mutated GNAS 
in vivo. 
Exogenous expression of GNAS induced cAMP elevation; however, the degree of 
this elevation varied according to cell type. PK-8 cells showed a marked increase in cAMP, 
whereas PCI-35 and MIA PaCa-2 cells exhibited a lesser degree of elevation. This difference 
might be attributable to the endogenous robustness of G-protein signaling. The SAGE 
analysis revealed that the endogenous expression of GNAS in control (vector-transfected) 
cells was substantially higher in PK-8 than it was in PCI-35 and MIA PaCa-2 cells. The high 
expression of endogenous GNAS observed in PK-8 cells suggests that G-protein signaling is 
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robust and somewhat active in this cell type, and ready to respond to exogenous expression of 
GNAS. PK-8 cells exhibited the most remarkable alteration in gene expression induced by the 
exogenous expression of GNAS. 
The exogenous expression of mutated GNAS had no promoting effect on in vitro cell 
proliferation or anchorage-dependent growth. This indicates that mutated GNAS alone may 
not be sufficient to induce or maintain infinite growth, which is consistent with the finding 
that the genetically engineered mouse model of colon cancer with mutated GNAS does not 
exhibit tumorigenesis without synergistic molecular aberrations.
30)
 Instead, the exogenous 
expression of GNAS yielded a suppressive effect in some cells. A colony formation assay 
showed that the stable expression of wild-type or mutated GNAS suppressed the 
anchorage-dependent growth of PK-8 cells, the cells that were most sensitive to the 
exogenous expression of GNAS. This suppressive effect might be attributable to the 
unexpected activation of tumor-suppressive pathways or downregulation of tumor-promoting 
molecules. SAGE analysis revealed the downregulation of tumor-promoting genes, including 
SOCS1, ID1, PBXIP1, FKBPL, S100A6, STAP2, MARVELD1, and LGAL3BP (Table 3). 
These molecules were downregulated in PK-8 cells, but not in PCI-35 or MIA PaCa-2 cells. 
Gene ontology analysis showed that approximately 2/3 of the genes downregulated by the 
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exogenous expression of mutated GNAS were annotated as associated with cell proliferation 
and growth, which may interprete the suppressive effect in cell proliferation. GPCR pathway 
activation seemed to be lower in PCI-35 and MIA PaCa-2 cells than PK-8 cells, as shown by 
cAMP levels after the exogenous expression of GNAS, which interpreted differences in 
response for proliferation and anchorage-dependent growth of these cells after the exogenous 
expression of GNAS. 
The marked alteration of gene expression patterns observed in PK-8 cells induced by 
the exogenous expression of mutant GNAS is attributable to a significant elevation in cAMP 
levels. The elevation of cAMP is supposed to activate PKA and subsequently induce the 
expression of various downstream genes. Mucin gene expression was found to be consistently 
upregulated in the cells, which can be considered as being compatible with the main feature of 
IPMN, i.e., abundant mucin secretion. Moreover, some genes in the PI3K–AKT pathway that 
have been reported as being upregulated in IPMN were also upregulated in the cells.
21)
 These 
results indicate that PK-8 expressing mutant GNAS exogenously can be regarded as an in 
vitro model of IPMN. 
Some genes with altered expression patterns induced by the exogenous expression of 
mutated GNAS are interesting for understanding the phenotypes associated with the 
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upregulation of G-protein signaling (Fig. 6). ALDHA1 encodes aldehyde dehydrogenase 1 
family, member A1, which is serves as a marker of cancer-initiating cells and correlates with 
tumorigenicity.
31)
 CD55 or DAF, the decay-accelerating factor, encodes a protein of the 
membrane-bound complement regulatory protein family, which is a known target of the 
MAPK pathway,
32)
 and is consistent with the fact that genes located downstream of the 
MAPK pathway were mostly upregulated (Fig. 8). CREB1 encodes the cAMP responsive 
element-binding protein 1 (CREB1), which functions as a transcription factor that is primarily 
controlled by PKA, but also by MSK-1, in the MAPK pathway, and by AKT in the 
insulin-like growth factor pathway.
33-36)
 CREB1 can modify the expression of diverse proteins 
involved in metabolism, transcription, cell cycle, and neuropeptide, growth factor, and mucin 
expression.
22-24)
 DDIT4 encodes the DNA-damage-inducible transcript 4, also known as 
REDD1, which is a negative regulator of mammalian target of rapamycin (mTOR) and a 
possible tumor suppressor in renal cell carcinoma.
37, 38)
 The increase in DDIT4 transcription 
observed in PK-8 cells induced by mutated GNAS may indicate a suppressive effect of GNAS 
on tumorigenesis. GNB2 encodes the G-protein, beta polypeptide 2, which is associated with 
the NF-kappaB signaling pathway and tumorigenesis.
39)
 GNG10 encodes the G-protein, 
gamma 10 and is mutated in melanoma.
40)
 LCN2, also known as NGAL, encodes lipocalin 2, 
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which is a neutrophil gelatinase-associated lipocalin that contributes to tumor progression.
41, 
42)
 Lipocalin 2 is also known as an adipokine that is upregulated by insulin via the PI3K and 
MAPK signaling pathways.
43)
 MIA3, also known as TANGO, encodes the melanoma 
inhibitory activity family, member 3, which shows tumor-suppressor activities in colon and 
hepatocellular carcinoma, as well as malignant melanoma.
44)
 PHLPP1 encodes the PH 
domain and leucine-rich repeat protein phosphatase 1, which dephosphorylates AKT
45)
 and 
suppresses the growth of colon cancer and glioblastoma cells.
46)
 PIK3CA encodes the 
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha, which is mutated in 
many human tumors, including IPMNs.
47, 48)
 
Based on the expression profiling, the exogenous expression of mutant GNAS 
induced alterations in expressions of genes involved in the PI3K–AKT and MAPK signaling 
pathways. In PK-8 cells, some genes involved in the PI3K–AKT pathway were upregulated, 
whereas those involved in the MAPK pathway were downregulated, which is affected by the 
activation of G-protein signaling. Inactivation of MAPK consistently downregulated mucin 
gene expression in PCI-35 cells; however, the effects of the MAPK inactivation in PK-8 cells 
were complicated, as it downregulated MUC2 but upregulated MUC5AC. This result indicates 
that the MAPK pathway plays a primary role (i.e., G-protein signaling may play a limited 
 31 
role) in the regulation of mucin gene expression in PCI-35 cells. In contrast, G-protein 
signaling may play a primary and consistent role in the promotion of mucin gene expression; 
however, the relations between G-protein and MAPK signaling can be complicated in PK-8 
cells (Fig. 11A and B). As shown in Fig. 9, mutated GNAS induced downregulation of gene 
expressions on MAPK pathway, therefore inhibition of MAPK pathway by U-0126 may lead 
to consistent upregulation of MUC5AC in PK-8 cells (Fig. 10D). A balance of activities 
between these signaling pathways could result in complicated gene expression control 
processes.  
Although MAPK was uncovered to contribute to mucin gene expression in the 
experiments using U0126 (Fig. 10C and D), the degree of mucin gene expression changing 
among the controls (DMSO added) was relatively modest compared to that in Fig. 5A and B, 
especially in PCI-35 cells. Administration of DMSO in experiments of Fig. 10 was the only 
difference between these experiments. Preliminary experiments to investigate the effects of 
DMSO on mucin gene expression in PCI-35 revealed suppressive effects on gene expression 
up to 9.5% compared to controls when 0.5% (v/v) of DMSO was administered in culture 
medium (data not shown). Furthermore, DMSO is reported to change the DNA methylation 
state and subsequently alter gene expressions; therefore, addition of DMSO can cause the 
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apparent somewhat disparate results between experiments shown in Fig. 5 and Fig. 10.
49, 50)
  
Although mutant GNAS induced radical alterations of expression profiles of genes 
comprising PI3K–AKT and MAPK signaling pathways, mutated GNAS did not seem to 
directly alter the expression patterns of the phosphorylated key molecules in these pathways, 
ERK and AKT (Fig. 2A). These apparently discrepant findings may potentially be due to 
difference in timing of expression, i.e., gene expression alters shortly after the transfection 
procedure but the change of transmission signaling like phosphorylation may require longer 
time than that of gene expression. Experiments using stably transfected cells can reflect the 
gene expression changes on phosphorylation in signaling pathways as long-term effects. 
Previous reports showed that MAPK induces MUC2 and MUC5AC gene expressions 
in respiratory epithelial cells in inflammatory settings of in vitro experiments.
23, 24, 51-53)
 
MUC2 and MUC5AC are known to be common secreted proteins reacting to the 
inflammation, hence these gene expressions have been well-studied in respiratory epithelial 
cells. However, few articles showed the relationship between MAPK and gene expressions of 
MUC2 and MUC5AC in cancer cells. Furthermore, the regulation of MUC2 and MUC5AC via 
MAPK pathway in pancreatic cancer cell lines is a novel finding that has been previously 
unreported. Understanding the role of MUC2 and MUC5AC related to the MAPK pathway 
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may shed light on the pathogenesis of pancreatic neoplasms including IPMN. 
In this study, we have shown for the first time that PK-8 cells with exogeneous 
GNAS expression can be used as an ideal model of IPMN. Highly GPCR-dependent character 
of PK-8 cells which was revealed by SAGE analysis can be reasonable as a model of IPMN 
with mutated GNAS. In this PK-8 cells, mutated GNAS induces global alterations of gene 
expressions including the upregulation of MUC2 and MUC5AC. Taken together, we provide 
new insight into the role of mutated GNAS in IPMN, i.e. facilitation of mucin secretion.  
Clinically, acute pancreatitis repeatedly occurs in IPMN patients due to the 
obstruction of pancreatic duct, with its viscous discharge. Inhibition of activated GPCR 
pathway, which is induced by mutated GNAS, may decrease the excessive secretion into the 
pancreatic duct, leading to the potent treatment of repeated acute pancreatitis in IPMN. 
Progression into pancreatic cancer from IPMN is another clinical problem as well. This study 
contributes to understanding of the nature of IPMN from the viewpoint of mucin gene 
expression and GNAS. IPMN is classified into four distinct pathological types, namely, gastric 
type, intestinal type, pancreatobiliary type, and oncocytic type, based on histomorphological 
variation of neoplastic papillae and expression of distinct mucin expression.
25)
 The 
gastric-type IPMN shows thick-finger like papillae expressing MUC5AC, the intestinal-type 
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IPMN shows villous papillae expressing MUC2 and MUC5AC, the pancreatobiliary-type 
IPMN shows complex branching papillae expressing MUC1 and MUC5AC, and the 
oncocytic-type IPMN shows fractal-like papillae expressing MUC5AC and MUC6. In other 
words, MUC5AC is a common type of mucin for IPMNs whereas MUC2 is a specific type of 
mucin only for the intestinal-type IPMN. Interestingly, these IPMN types are associated with 
progression to distinct types of invasive carcinoma and patients’ prognosis.
6)
 The 
intestinal-type IPMN is associated with mucinous colloid carcinoma that reveals better 
prognosis than tubular adenocarcinoma that usually associated with the gastric-type or the 
pancreatobiliary-type IPMNs. Hence, expression of discrete mucin proteins can be an 
important pathobiological marker for progression of IPMN. In our study, MUC2 and 
MUC5AC were appeared to be differentially regulated by synergistic or contrary interaction 
of G-protein signaling and MAPK signaling. This result suggests that interaction of signaling 
pathways may underlie not only regulation of mucin expression but also progression of 
IPMNs into different types and association of invasive carcinoma, which is an important issue 
to be studied further in detail to elucidate molecular mechanisms of development and 
progression of IPMN.    
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Conclusion 
The mutation in GNAS found in IPMNs can play a pivotal role in altering gene expression 
profiles, with mucin gene expression change in the cell line of pancreatic ductal cell origin. 
PK-8 cells expressing mutated GNAS exogenously can be used as an ideal in vitro model of 
IPMN.  
 
Abbreviations 
Vec, pcDNA 3.1/V5-His vector transfected cells; GW, pcDNA3.1/V5-His-wild GNAS vector 
transfected cells; GM, pcDNA3.1/V5-His-mutant GNAS vector transfected cells 
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Figure legends 
Fig. 1 Transfection efficiency in PK-8, PCI-35 and MIA PaCa-2. The pcDNA 3.1/mutant 
GNAS-V5-His vector was transfected into cells, then evaluated by immunofluorescence 
detection of recombinant proteins with V5 epitope tags. Fluorescent images are superposed on 
normal images. Efficiency is similar among the three cell lines (12.3%, 13.7% and 12.7% in 
PK-8, PCI-35 and MIA PaCa-2, respectively).   
 
Fig. 2. Exogenous expression of GNAS induces cAMP elevation in pancreatic cancer cell 
lines, PK-8, PCI-35, and MIA PaCa-2. (A) Immunoblots of total lysates of cells transfected 
with the vector (Vec), the wild-type GNAS-V5 (GW), and the mutated GNAS-V5 (R201H) 
(GM) probed with antibodies indicated in the left column. (B) cAMP measured by the 
enzyme immunoassay. Exogenous expression of GNAS induced cAMP elevation, especially 
in the transfectants with mutated GNAS. Values of independently duplicated experiments 
were plotted with the range of one standard error and statistically compared. A single asterisk 
indicates p < 0.05, two asterisks indicate p < 0.01.  
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Fig. 3. Colony formation assay shows effects of the exogenous expression of GNAS on cell 
anchorage-dependent growth.  (A) Colony formations of cells transfected with the vector 
(Vec), the wild-type GNAS (GW), and the mutated GNAS (R201H) (GM) are shown. Mock 
denotes cells without transfection. (B) The mean values of total areas of surviving colonies 
were shown as relative values to those of Vec. Each transfection is consisted of three plates 
and mean values of independent triplicated (PK-8) or duplicated (PCI-35 and MIA PaCa-2) 
experiments in total were plotted with the range of one standard error and statistically 
compared. Two asterisks indicate p < 0.01. Exogenous expression of GNAS induced no 
promotion but some suppression of anchorage-dependent growth in PK-8 while no significant 
changes in PCI-35 or MIA PaCa-2. 
 
Fig. 4. (A) Colorimetric proliferation assay shows no promotion of cell proliferation by the 
transient exogenous expression of GNAS. Plotted were the mean value with one standard error 
of relative absorbance values at 3 days after transfection to those at the day of transfection. A 
single asterisk indicates p < 0.05 and two asterisks indicate p < 0.01. GM, cells transfected 
with mutated GNAS; GW, cells transfected with wild-type GNAS; and Vec, cells transfected 
with vector. (B) Cell cycle assay shows no alterations of cell cycles by the exogenous 
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expression of GNAS. DNA was stained with propidium iodide and its abundance in cells was 
detected by measuring florescence intensity using flow cytometry. GM, cells transfected with 
mutated GNAS; GW, cells transfected with wild-type GNAS; and Vec, cells transfected with 
vector.  
 
Fig. 5. Exogenous expression of GNAS induces alteration of mucin gene expressions in 
pancreatic cancer cell lines, PK-8, PCI-35, and MIA PaCa-2. Quantitaive real time PCR assay 
of MUC2 (A) and MUC5AC (B). Data was shown in logarithmic scale. Values of 
independently duplicated experiments were plotted with the range of one standard error and 
statistically compared. A single asterisk indicates p < 0.05, two asterisks indicate p < 0.01. 
Exogenous expression of GNAS upregulated MUC2 and MUC5AC in PK-8 but 
downregulated in PCI-35 and MIA PaCa-2. 
 
Fig. 6. An algorithm for choosing genes of different expressions in SAGE analysis.  
 
Fig. 7. Validation of SAGE data by semiquantitative PCR assay. Total RNA obtained from 
PK-8 transfected with vector (Vec) or the mutated GNAS (G201H) (GM), which was used in 
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SAGE analysis, was reverse-transcribed and used for PCR with primers listed in Table 3. The 
optimized cycling conditions were determined for each gene, and the expression of GAPDH 
was monitored as an internal control. Intensities of bands were digitally measured and 
illustrated with bar graphs below the images. Intensity of GM was demonstrated as relative 
value to Vec (%). Gene expression values in the SAGE analysis were also shown at the 
bottom. Refer to the text for the selection criteria of these genes from the SAGE results.    
 
Fig. 8. Alterations of gene expressions in signaling pathways. Genes of altered expressions in 
the ratio of the mutated GNAS transfectants to vector transfectants (GM/Vec) % 4 or & 0.25 in 
PK-8 in SAGE data were mapped on “Pathways in Cancer” in “Pathway Mapping” available 
from KEGG (http://www.genome.jp/kegg/). Panel A indicates upregulated genes while panel 
B indicates downregulated genes.   
 
Fig. 9. Altered expression of genes in signaling pathways by the exogenous expression of the 
mutated GNAS (R201H). Genes in PI3K-AKT and MAPK signaling pathways in Pathway 
Mapping available from KEGG were mapped with color labels according to the ratio of 
expression in cells of the mutated GNAS transfected (GM) to that in cells of the vector 
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transfected (Vec) obtained from the SAGE data (http://www.genome.jp/kegg/).
19)
 Gene 
expressions were changed drastically in PK-8 but little in PCI-35 or MIA PaCa-2.   
 
Fig. 10. MAPK activity contributes to mucin gene expressions. (A) Immunoblots of total 
lysate of cells transfected with the vector (Vec), the wild-type GNAS-V5 (GW), and the 
mutated GNAS-V5 (R201H) (GM) with or without treatment with U0126, a potent mitogen 
activated protein kinase kinase inhibitor. (B) cAMP measured by the enzyme immunoassay. 
Inhibition of ERK induced no alterations in cAMP levels. (C and D) Quantitaive real time 
PCR assay of MUC2 (C) and MUC5AC (D). MUC2 expression was downregulated in both 
PK-8 and PCI-35 while MUC5AC was upregulated in PK-8 but downregulated in PCI-35 by 
ERK inhibition. Graphs show the mean values with one standard error of independently 
duplicated experiments. A single asterisk indicates p < 0.05, two asterisks indicate p < 0.01.  
 
Fig.11 Schematic pathway for MUC2 and MUC5AC expressions in PK-8 cells. GPCR 
pathway induces MUC2 and MUC5AC upregulation, while MAPK pathway has inverse effect 
on MUC2 and MUC5AC gene expressions. “A” in a circle, supposed transcription gene for 
mucin.
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Table 1. Primers for semiquantitative PCR 
Gene names Forward primers (5’-3’) Reverse primers (5’-3’) 
GAPDH AGGTGGTGAAGCAGGCGTCG ACCCTGTTGCTGTAGCCAAATTCG 
ALDH1A1 GGGTGAATTGCTATGGCGTG TGAAGAGCTTCTCTCCACTCTTG 
C3orf37 CTCCTGTCGACTTGGTGGTC GGACCACTGGGGAACATCTG 
CD55 CACCACCTGAATGCAGAGG CTAGCGTCCCAAGCAAACC 
CREB1 CCCCAGCACTTCCTACACAG CTTTCAGGTTGTGGCCAAGC 
DDIT4 GTTCATCAGCAAACGCCCTG GACACCCCATCCAGGTAAGC 
GNB2 ATCCGACATCAATGCAGTGGC GCCATGCCATCGTCGGTGAC 
GNG10 CTGGCGTGGAGAGGATCAAG GCTATAGGACCAGGCCACAG 
LCN2 AACCAAGGAGCTGACTTCGG AGCTCCCTCAATGGTGTTCG 
MIA3 CCCTGTACCACCACCCATTC GTGGTGGTGGGTATTCCTGG 
PHLPP1 AAGCATGACCCTGTGGATCC CACACTGGGATGGAGGAAGG 
PIK3CA AAAGGAGCCCAAGAATGCAC GTTGTCCAGCCACCATGATG 
SH3BGRL GCAGCCAATGAAGAGAATCGG AGGTTCATGCTTGCTGCTTTG 
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Table 2. Mucin expression profiles in SAGE analysis 
!  PK-8  PCI-35  MIA PaCa-2  
Gene  Vec  GM  
Change 
(GM/Vec)  
Vec  GM  
Change 
(GM/Vec)  
Vec  GM  
Change 
(GM/Vec)  
MUC1 4.35 3.30 Down 7.25 8.18 Up 3.54 4.58 Up 
MUC2 ND -2.49 Up ND ND - ND ND - 
MUC5B ND -1.49 Up -1.72 -3.37 Down ND ND - 
MUC6 ND -2.49 Up ND ND - -3.01 ND Down 
MUC15 1.66 2.91 Up 2.34 2.56 Up 1.90 1.72 Down 
MUC16 -1.40 ND Down 1.87 2.33 Up ND ND - 
MUC20 3.12 3.22 Up 2.28 1.63 Down 1.57 0.67 Down 
MUCL1 1.02 0.32 Down ND ND - ND ND - 
The values were expressed in the binary logarithm value of reads per million (log2 RPM) 
obtained by SAGE analysis. Down, downregulated in GM compared to Vec; GM, cells 
transfected with mutated GNAS; ND, not detectable; Up, upregulated in GM compared to 
Vec; Vec, cells transfected with vector.  
 
Table 3. Representative genes downregulated in PK-8 by the exogenous expression of mutated GNAS
Gene
Symbol
Gene
ID
PK-8_
Vec
PK-8_
GM
PCI-
35_
Vec
PCI-
35_
GM
MIA
PaCa-2
_Vec
MIA
PaCa-2
_GM
biological process cellular component molecular function
BAD 572 5.2 -0.9 6.1 6.4 4.8 6.0 glucose catabolic process;apoptotic process;induction of apoptosis;activation of cysteine-type
endopeptidase activity involved in apoptotic process;epidermal growth factor receptor
signaling pathway;fibroblast growth factor receptor signaling pathway;response to glucose
stimulus;positive regulation of autophagy;positive regulation of mitochondrial membrane
potential;cytokine-mediated signaling pathway;positive regulation of insulin
secretion;response to estradiol stimulus;response to progesterone stimulus;positive
regulation of glucokinase activity;response to testosterone stimulus;response to oleic
acid;positive regulation of insulin secretion involved in cellular response to glucose
stimulus;response to drug;response to hydrogen peroxide;glucose homeostasis;positive
regulation of apoptotic process;response to amino acid stimulus;positive regulation of
cysteine-type endopeptidase activity involved in apoptotic process;type B pancreatic cell
proliferation;innate immune response;response to ethanol;positive regulation of B cell
differentiation;positive regulation of T cell differentiation;positive regulation of
proteolysis;ADP metabolic process;ATP metabolic process;regulation of mitochondrial
membrane permeability;pore complex assembly;neurotrophin TRK receptor signaling
pathway;phosphatidylinositol-mediated signaling;positive regulation of epithelial cell
proliferation;response to glucocorticoid stimulus;response to calcium ion;cellular process
regulating host cell cycle in response to virus;cellular response to chromate;cellular
response to mechanical stimulus;cellular response to nicotine;cellular response to
lipid;cellular response to hypoxia;positive regulation of release of cytochrome c from
mitochondria;apoptotic signaling pathway;extrinsic apoptotic signaling pathway;intrinsic
apoptotic signaling pathway;activation of cysteine-type endopeptidase activity;positive
regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling
pathway;positive regulation of type B pancreatic cell development;positive regulation of
intrinsic apoptotic signaling pathway
mitochondrion;mitochondrial outer
membrane;cytosol
protein binding;phospholipid binding;lipid
binding;cysteine-type endopeptidase activator
activity involved in apoptotic process;protein kinase
binding;protein phosphatase 2B binding;protein
kinase B binding;protein heterodimerization activity
SERPING1 710 2.9 -1.5 4.0 4.3 2.1 3.2 negative regulation of complement activation, lectin pathway;platelet
degranulation;complement activation, classical pathway;blood coagulation;blood
coagulation, intrinsic pathway;blood circulation;negative regulation of endopeptidase
activity;platelet activation;fibrinolysis;innate immune response
extracellular region;extracellular space;platelet
alpha granule lumen
serine-type endopeptidase inhibitor activity;protein
binding
RUNX1T1 862 4.5 -22.9 4.3 4.8 2.3 3.6 generation of precursor metabolites and energy;transcription, DNA-dependent;fat cell
differentiation;regulation of DNA binding
nuclear matrix DNA binding;sequence-specific DNA binding
transcription factor activity;protein binding;zinc ion
binding;identical protein binding;protein
homodimerization activity
CBS 875 6.1 1.9 -3.3 -1.4 6.6 7.2 sulfur amino acid metabolic process;endochondral ossification;blood vessel
remodeling;cysteine biosynthetic process from serine;L-serine metabolic process;L-serine
catabolic process;superoxide metabolic process;cysteine biosynthetic process via
cystathionine;transsulfuration;L-cysteine catabolic process;cerebellum
morphogenesis;regulation of cGMP metabolic process;cellular nitrogen compound metabolic
process;negative regulation of apoptotic process;homocysteine catabolic process;regulation
of JUN kinase activity;small molecule metabolic process;homocysteine metabolic
process;regulation of blood vessel size;response to folic acid;maternal process involved in
female pregnancy;cartilage development involved in endochondral bone
morphogenesis;hydrogen sulfide biosynthetic process;cellular response to hypoxia
nucleus;nucleolus;cytosol;intracellular membrane-
bounded organelle
cystathionine beta-synthase activity;protein
binding;enzyme binding;heme binding;pyridoxal
phosphate binding;ubiquitin protein ligase
binding;protein homodimerization activity;metal ion
binding;modified amino acid binding
FLT4 2324 3.1 -0.9 4.1 4.4 2.1 3.3 positive regulation of protein phosphorylation;positive regulation of endothelial cell
proliferation;vasculature development;lymph vessel
development;lymphangiogenesis;sprouting angiogenesis;transmembrane receptor protein
tyrosine kinase signaling pathway;positive regulation of cell proliferation;positive
regulation vascular endothelial growth factor production;positive regulation of endothelial
cell migration;peptidyl-tyrosine phosphorylation;cellular response to vascular endothelial
growth factor stimulus;negative regulation of apoptotic process;positive regulation of MAPK
cascade;positive regulation of JNK cascade;protein autophosphorylation;vascular
endothelial growth factor receptor signaling pathway;blood vessel morphogenesis;regulation
of blood vessel remodeling;positive regulation of ERK1 and ERK2 cascade;positive
regulation of protein kinase C signaling cascade
extracellular region;nucleus;cytoplasm;plasma
membrane;integral to plasma membrane
transmembrane receptor protein tyrosine kinase
activity;vascular endothelial growth factor-activated
receptor activity;protein binding;ATP binding;growth
factor binding;protein phosphatase binding
GJB3 2707 4.8 0.7 2.9 3.7 -0.7 -0.6 in utero embryonic development;placenta development;cell communication;sensory
perception of sound;skin development
cytoplasm;gap junction;connexon complex;integral to
membrane
gap junction channel activity
HSD3B2 3284 4.7 -0.9 6.2 6.7 3.9 6.0 steroid biosynthetic process;androgen biosynthetic process;glucocorticoid biosynthetic
process;mineralocorticoid biosynthetic process;steroid metabolic process;small molecule
metabolic process
mitochondrial inner membrane;mitochondrial
intermembrane space;endoplasmic
reticulum;endoplasmic reticulum membrane;integral
to membrane;smooth endoplasmic reticulum
membrane;mitochondrial membrane
3-beta-hydroxy-delta5-steroid dehydrogenase
activity;steroid delta-isomerase activity
ID1 3397 8.8 2.5 7.1 7.1 7.5 8.5 negative regulation of transcription from RNA polymerase II
promoter;angiogenesis;endothelial cell morphogenesis;transcription, DNA-
dependent;apoptotic process;transforming growth factor beta receptor signaling
pathway;heart development;negative regulation of transcription by transcription factor
localization;BMP signaling pathway;protein destabilization;collagen metabolic
process;negative regulation of DNA binding;regulation of MAPK cascade;negative
regulation of sequence-specific DNA binding transcription factor activity;blood vessel
endothelial cell migration;negative regulation of osteoblast differentiation;regulation of
angiogenesis;negative regulation of transcription, DNA-dependent;response to
antibiotic;blood vessel morphogenesis;lung morphogenesis;lung vasculature development
nucleus;cytoplasm sequence-specific DNA binding transcription factor
activity;protein binding;protein dimerization activity
KHK 3795 2.8 -2.5 -0.1 0.9 1.7 1.9 carbohydrate metabolic process;fructose catabolic process;small molecule metabolic process cytoplasm;cytosol ketohexokinase activity;ATP binding
LGALS3BP 3959 9.9 5.9 8.6 8.7 3.6 3.7 cellular defense response;cell adhesion;signal transduction proteinaceous extracellular matrix;extracellular
space;membrane;extracellular matrix;extracellular
vesicular exosome
scavenger receptor activity
MMP7 4316 2.2 -2.5 3.3 4.1 0.9 2.5 antibacterial peptide secretion;proteolysis;extracellular matrix disassembly;extracellular
matrix organization;collagen catabolic process;regulation of cell proliferation;response to
drug;defense response to Gram-negative bacterium;defense response to Gram-positive
bacterium
extracellular region;proteinaceous extracellular
matrix;extracellular space
metalloendopeptidase activity;zinc ion binding
PPOX 5498 5.4 0.3 5.3 6.3 4.8 5.5 porphyrin-containing compound metabolic process;porphyrin-containing compound
biosynthetic process;protoporphyrinogen IX biosynthetic process;heme biosynthetic
process;response to drug;small molecule metabolic process;oxidation-reduction process
mitochondrial intermembrane space;intrinsic to
mitochondrial inner membrane;integral to
mitochondrial inner membrane;mitochondrial
membrane
oxygen-dependent protoporphyrinogen oxidase
activity;flavin adenine dinucleotide binding
S100A6 6277 9.1 4.6 10.2 10.3 9.1 10.1 signal transduction;axonogenesis;positive regulation of fibroblast proliferation ruffle;nucleus;nuclear
envelope;cytoplasm;cytosol;extrinsic to internal side
of plasma membrane;perinuclear region of cytoplasm
calcium ion binding;protein binding;tropomyosin
binding;zinc ion binding;ion transmembrane
transporter activity;protein homodimerization
activity;S100 protein binding;calcium-dependent
protein binding
CCL14 6358 2.0 -22.9 2.7 3.0 1.1 2.8 cellular calcium ion homeostasis;immune response;positive regulation of cell proliferation extracellular space chemokine activity
TFAP4 7023 7.2 3.0 6.5 6.5 5.5 5.5 protein complex assembly;DNA damage response, signal transduction by p53 class mediator
resulting in transcription of p21 class mediator;negative regulation of cell
proliferation;positive regulation of apoptotic process;negative regulation of apoptotic
process;negative regulation of DNA binding;negative regulation by host of viral
transcription;positive regulation by host of viral transcription;negative regulation of cyclin-
dependent protein serine/threonine kinase activity;negative regulation of transcription,
DNA-dependent;positive regulation of transcription, DNA-dependent;negative regulation of
cell cycle arrest;cellular response to dexamethasone stimulus
nucleus;transcriptional repressor complex DNA binding;RNA polymerase II distal enhancer
sequence-specific DNA binding transcription factor
activity;transcription coactivator activity;protein
binding;protein homodimerization activity;histone
deacetylase binding;sequence-specific DNA
binding;transcription regulatory region DNA
binding;protein heterodimerization activity;E-box
binding
SOCS1 8651 2.4 -22.9 0.5 2.1 3.2 4.6 regulation of protein phosphorylation;negative regulation of protein kinase activity;JAK-
STAT cascade;protein ubiquitination;cytokine-mediated signaling pathway;regulation of
growth;negative regulation of tyrosine phosphorylation of Stat3 protein;fat cell
differentiation;negative regulation of JAK-STAT cascade;negative regulation of insulin
receptor signaling pathway;interferon-gamma-mediated signaling pathway;regulation of
interferon-gamma-mediated signaling pathway;type I interferon-mediated signaling
pathway;regulation of type I interferon-mediated signaling pathway;JAK-STAT cascade
involved in growth hormone signaling pathway;cellular response to amino acid stimulus
nucleus;cytoplasm;cytosol;cytoplasmic membrane-
bounded vesicle
protein kinase inhibitor activity;insulin-like growth
factor receptor binding;protein binding;kinase
inhibitor activity;protein kinase binding
FBP2 8789 2.3 -22.9 3.8 4.1 2.2 3.4 carbohydrate metabolic process;fructose metabolic process;glucose metabolic
process;gluconeogenesis;small molecule metabolic process
cytosol fructose-2,6-bisphosphate 2-phosphatase
activity;fructose 1,6-bisphosphate 1-phosphatase
activity;metal ion binding
BCL7C 9274 4.0 -1.5 3.0 3.6 3.7 4.4 apoptotic process
RCE1 9986 6.2 1.2 5.5 5.6 5.1 5.3 proteolysis;CAAX-box protein processing endoplasmic reticulum membrane;integral to plasma
membrane
cysteine-type endopeptidase
activity;metalloendopeptidase activity
ATF5 22809 5.3 1.2 2.8 3.2 6.2 6.7 transcription, DNA-dependent;regulation of transcription from RNA polymerase II
promoter;negative regulation of apoptotic process;negative regulation of astrocyte
differentiation
nucleus;transcription factor
complex;nucleolus;cytoplasm
sequence-specific DNA binding transcription factor
activity;transcription corepressor activity;protein
binding;heat shock protein binding;sequence-specific
DNA binding
GRAMD4 23151 5.4 0.1 3.1 3.2 4.3 5.2 apoptotic process integral to membrane;mitochondrial membrane
ABTB2 25841 6.8 1.6 5.4 5.6 5.2 5.3 regulation of cell growth cellular_component molecular_function;protein heterodimerization
activity
FBXO2 26232 3.5 -0.5 3.9 4.0 6.0 6.2 cellular protein modification process;proteolysis;glycoprotein catabolic process;protein
ubiquitination;ER-associated protein catabolic process;SCF-dependent proteasomal
ubiquitin-dependent protein catabolic process;regulation of protein ubiquitination
endoplasmic reticulum;cytosol;SCF ubiquitin ligase
complex;organelle membrane;dendritic spine
beta-amyloid binding;glycoprotein binding;ubiquitin-
protein ligase activity;carbohydrate binding
REPIN1 29803 2.1 -2.5 5.0 5.7 5.6 6.3 regulation of fatty acid transport;regulation of glucose import in response to insulin
stimulus
nucleus;lipid particle;cytosolic ribosome;nuclear
membrane
nucleic acid binding;zinc ion binding
CDR2L 30850 5.0 0.8 2.4 3.7 5.1 5.2
C11orf71 54494 2.4 -2.5 3.3 3.5 1.7 2.7
STAP2 55620 5.5 1.2 5.8 5.9 0.2 1.1 DNA binding;zinc ion binding
ADAMTS9 56999 5.4 1.4 5.0 5.1 5.1 5.4 proteolysis;glycoprotein catabolic process;multicellular organismal development;positive
regulation of melanocyte differentiation
proteinaceous extracellular matrix;extracellular
space;extracellular matrix
metalloendopeptidase activity;metallopeptidase
activity;zinc ion binding
PBXIP1 57326 4.2 -1.5 3.1 4.0 2.7 3.4 multicellular organismal development;cell differentiation;negative regulation of
transcription, DNA-dependent
nucleus;cytoplasm;cytosol;microtubule;intracellular
membrane-bounded organelle
transcription corepressor activity;protein binding
CAMSAP3 57662 3.7 -0.5 1.9 2.3 0.3 1.1 plasma membrane;postsynaptic density;integral to
membrane;cell junction;postsynaptic membrane
FKBPL 63943 6.2 1.0 4.5 4.9 4.8 5.2 protein peptidyl-prolyl isomerization;response to radiation;peptidyl-proline modification nucleus;membrane peptidyl-prolyl cis-trans isomerase activity;FK506
binding
PORCN 64840 5.2 0.8 3.0 3.9 3.3 3.9 glycoprotein metabolic process;Wnt receptor signaling pathway integral to endoplasmic reticulum membrane transferase activity, transferring acyl groups
MRPL41 64975 4.3 -0.9 5.4 5.6 5.9 6.5 translation;apoptotic process;cell cycle mitochondrion;mitochondrial large ribosomal
subunit;ribonucleoprotein complex
structural constituent of ribosome
KREMEN2 79412 3.7 -22.9 3.9 4.1 4.4 4.6 Wnt receptor signaling pathway integral to membrane
ZNF768 79724 7.3 2.9 5.8 6.0 7.2 7.3 regulation of transcription, DNA-dependent;transcription from RNA polymerase II
promoter
DNA-directed RNA polymerase II, core complex DNA binding;zinc ion binding
RERGL 79785 3.4 -0.9 4.9 6.1 2.2 4.6 small GTPase mediated signal transduction membrane GTPase activity;GTP binding
HSD3B7 80270 4.6 0.1 1.9 2.4 6.6 6.7 bile acid biosynthetic process;bile acid metabolic process;small molecule metabolic process cellular_component;endoplasmic reticulum
membrane;integral to membrane
3-beta-hydroxy-delta5-steroid dehydrogenase
activity;cholest-5-ene-3-beta,7-alpha-diol 3-beta-
dehydrogenase activity
MARVELD1 83742 6.3 2.0 5.8 6.6 5.3 6.0 cell cycle nucleus;cytoplasm;cytoskeleton;plasma
membrane;integral to membrane
NUDT16L1 84309 5.4 1.0 5.0 5.8 4.4 4.9 cytoplasm snoRNA binding;protein homodimerization
activity;m7G(5')pppN diphosphatase activity
LZTS2 84445 6.7 0.3 5.3 5.7 5.5 5.6 mitosis;Wnt receptor signaling pathway;cell division cytoplasm;microtubule organizing
center;microtubule
protein binding
PHF5A 84844 4.7 0.3 5.5 5.7 2.8 4.3 mRNA splicing, via spliceosome;transcription, DNA-dependent;RNA splicing;gene
expression;positive regulation of transcription, DNA-dependent
nucleoplasm;U2 snRNP;U12-type spliceosomal
complex;nuclear matrix;nuclear speck
DNA binding;sequence-specific DNA binding
transcription factor activity
CCDC65 85478 1.5 -2.5 3.0 3.3 -0.4 1.7
MIDN 90007 7.0 2.2 6.2 6.5 4.2 5.1 nucleolus
LMTK3 114783 2.5 -2.5 3.5 4.0 -3.0 -0.6
C6orf192 116843 6.4 1.8 5.4 5.6 1.6 1.9
C6orf57 135154 2.8 -22.9 2.4 2.4 2.3 2.7 extracellular region;mitochondrion
TMC4 147798 3.0 -1.5 0.0 0.8 -22.9 -3.4 ion transport integral to membrane
PSORS1C2 170680 2.1 -2.5 3.5 4.0 1.7 2.7 biological_process cellular_component;extracellular region molecular_function
SLC16A13 201232 2.5 -2.5 -0.1 0.2 0.2 1.3 plasma membrane;integral to membrane symporter activity
UNC5B 219699 4.3 0.1 0.8 1.4 2.7 3.0 apoptotic process;signal transduction;axon guidance;regulation of apoptotic process;negative
regulation of extrinsic apoptotic signaling pathway in absence of ligand
integral to membrane protein binding
INO80E 283899 7.8 3.3 6.3 6.8 7.6 7.8 DNA replication;DNA repair;DNA recombination;transcription, DNA-dependent;regulation
of transcription, DNA-dependent
nucleus;nucleolus;Ino80 complex protein binding
GPR153 387509 4.2 -0.2 3.7 4.8 3.2 3.7 plasma membrane;integral to membrane G-protein coupled receptor activity
Abbreviations: GM, pcDNA3.1/V5-His-mutant GNAS vector transfected cells; Vec, pcDNA 3.1/V5-His vector transfected cells
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